{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}],"title":"Baseline MRD Unknown"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}],"title":"Baseline MRD 10^-5"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}],"title":"Baseline MRD 10^-4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"2"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"}]}],"title":"Baseline MRD 10^-3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"2"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"}]}],"title":"Baseline MRD 10^-2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"2"}]}],"title":"Baseline MRD 10^-1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"2"}],"units":"Participants"}],"description":"MRD level was measured by polymerase chain reaction (PCR) performed on bone marrow and assessed by the central laboratory. An MRD level of 10\\^-n corresponds to residual leukemia cells at a frequency of 1 per 10ⁿ bone marrow cells.","groups":[{"description":"Participants with an MRD level 10\\^-5 at the end of cycle 1.","id":"OG000","title":"Cycle 1 MRD 10^-5"},{"description":"Participants with an MRD level 10\\^-4 at the end of cycle 1.","id":"OG001","title":"Cycle 1 MRD 10^-4"},{"description":"Participants with an MRD level 10\\^-3 at the end of cycle 1.","id":"OG002","title":"Cycle 1 MRD 10^-3"},{"description":"Participants with an MRD level 10\\^-2 at the end of cycle 1.","id":"OG003","title":"Cycle 1 MRD 10^-2"},{"description":"Participants with an MRD level 10\\^-1 at the end of cycle 1.","id":"OG004","title":"Cycle 1 MRD 10^-1"},{"description":"Participants with an unknown MRD level at the end of cycle 1.","id":"OG005","title":"Cycle 1 MRD Unknown"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Full analysis set participants who were in hematological complete remission at treatment start, with no MRD Response in the first treatment cycle, excluding Philadelphia-positive participants.","reportingStatus":"POSTED","timeFrame":"Baseline and end of cycle 1 (6 weeks)","title":"Change in MRD Level From Baseline to End of Cycle 1 in Non-MRD Responders","type":"SECONDARY","unitOfMeasure":"Participants"}